JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Craig, C. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Craig, C. R.
Journal of Pharmacology And Experimental Therapeutics, Vol. 153, Issue 2, 337-343, 1966
Copyright © 1966 by American Society for Pharmacology and Experimental Therapeutics

ANTICONVULSANT ACTIVITY OF STEROIDS: SEPARABILITY OF ANTICONVULSANT FROM HORMONAL EFFECTS

Charles R. Craig 1

1 Division of Biological Research, G. D. Searle & Co., Chicago, Illinois

In order to determine whether anticonvulsant effects and hormonal properties are intimately related among steroid compounds, the anticonvulsant activity of progesterone, desoxyconticosterone and other steroids was explored in mice. This activity was shown not to be a general characteristic of steroid compounds or to be closely associated with progestational or other hormonal effects. A series of 3beta-(aminoalkyl) esters of pregnenolone were examined for anticonvulsant activity, and the most active compound, 3beta-(3-N-pyrrolidinylpropionyloxy)-5-pnegnen-20-One (SC-10024), was additionally tested and was found to be devoid of hormonal effects. A brief clinical trial with SC-10024 showed it to exert beneficial effects in patients with epilepsy even though its activity was of such a low order that it precluded further testing.

Accepted on March 10, 1966




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. S. Reddy, D. C. Castaneda, B. W. O'Malley, and M. A. Rogawski
Anticonvulsant Activity of Progesterone and Neurosteroids in Progesterone Receptor Knockout Mice
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 230 - 239.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. Foldvary-Schaefer and T. Falcone
Catamenial epilepsy: Pathophysiology, diagnosis, and management
Neurology, September 1, 2003; 61(90062): S2 - 15.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
D. S. Reddy and M. A. Rogawski
Stress-Induced Deoxycorticosterone-Derived Neurosteroids Modulate GABAA Receptor Function and Seizure Susceptibility
J. Neurosci., May 1, 2002; 22(9): 3795 - 3805.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. G. Kokate, M. K. Banks, T. Magee, S.-I. Yamaguchi, and M. A. Rogawski
Finasteride, a 5alpha -Reductase Inhibitor, Blocks the Anticonvulsant Activity of Progesterone in Mice
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 679 - 684.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. B. Carter, P. L. Wood, S. Wieland, J. E. Hawkinson, D. Belelli, J. J. Lambert, H. S. White, H. H. Wolf, S. Mirsadeghi, S. H. Tahir, et al.
Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042; 3alpha -Hydroxy-3beta -methyl-5alpha -pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the gamma -Aminobutyric AcidA Receptor
J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1284 - 1295.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
S. C. Schachter
Hormonal Considerations in Women With Seizures
Arch Neurol, November 1, 1988; 45(11): 1267 - 1270.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics.